Vestal Point Capital, LP Astria Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
A detailed history of Vestal Point Capital, LP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 3,250,000 shares of ATXS stock, worth $37.6 Million. This represents 2.21% of its overall portfolio holdings.
Number of Shares
3,250,000
Previous 1,100,000
195.45%
Holding current value
$37.6 Million
Previous $15.5 Billion
91.02%
% of portfolio
2.21%
Previous 1.28%
Shares
2 transactions
Others Institutions Holding ATXS
# of Institutions
105Shares Held
49.6MCall Options Held
27.6KPut Options Held
29.7K-
Perceptive Advisors LLC New York, NY6.49MShares$75.1 Million1.71% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.04MShares$58.4 Million0.69% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$41.8 Million3.6% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$41.2 Million6.42% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$40.7 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $176M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...